Fig. 5: Combination therapy induces favorable immunogenicity compared to monotherapies.
From: DNA based neoepitope vaccination induces tumor control in syngeneic mouse models
a Representation of the timeline in the in vivo experiment. Groups of n = 13–15 BALB/c mice were immunized prophylactically with 3 µg of pCT26-13 DNA before s.c. inoculation with CT26 tumor cells. Administration of αPD-1 or isotype control antibody was initiated when untreated control tumors reached an average volume of approximately 100 mm3. Naïve control mice (no immunizations and no tumor inoculation) were housed together with experimental mice in a mixed cage setup. b Peptide pool re-stimulation and intracellular cytokine staining for IFNγ and TNFα producing CD4+ and CD8+ T cells on bulk splenocytes (n = 2–5 mice per group, mean ± SD). c Peptide pool re-stimulation and IFNγ ELISpot on splenocytes (n = 3 mice per group, mean ± SD). d Tumor digests single cell suspensions stained after termination with neoepitope C1 and C2-MHC multimers to monitor the frequency of antigen-specific CD8+ T cells (n = 4–5 mice per group, mean ± SD).
